Free Trial

Vera Therapeutics (VERA) Stock Price, News & Analysis

Vera Therapeutics logo
$28.58 -1.03 (-3.48%)
Closing price 02/21/2025 04:00 PM Eastern
Extended Trading
$29.29 +0.71 (+2.48%)
As of 02/21/2025 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Vera Therapeutics Stock (NASDAQ:VERA)

Key Stats

Today's Range
$28.34
$30.88
50-Day Range
$27.46
$43.96
52-Week Range
$25.99
$51.61
Volume
1.21 million shs
Average Volume
982,205 shs
Market Capitalization
$1.81 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.44
Consensus Rating
Buy

Company Overview

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Vera Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
43rd Percentile Overall Score

VERA MarketRank™: 

Vera Therapeutics scored higher than 43% of companies evaluated by MarketBeat, and ranked 664th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vera Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Vera Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Vera Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Vera Therapeutics are expected to decrease in the coming year, from ($2.89) to ($3.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vera Therapeutics is -10.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vera Therapeutics is -10.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Vera Therapeutics has a P/B Ratio of 14.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Vera Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    16.56% of the float of Vera Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Vera Therapeutics has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Vera Therapeutics has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Vera Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Vera Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.56% of the float of Vera Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Vera Therapeutics has a short interest ratio ("days to cover") of 12.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Vera Therapeutics has recently increased by 11.11%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Vera Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Vera Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    Only 2 people have searched for VERA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    10 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vera Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,305,625.00 in company stock.

  • Percentage Held by Insiders

    21.70% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vera Therapeutics' insider trading history.
Receive VERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VERA Stock News Headlines

Vera Therapeutics selloff a buying opportunity, says Evercore ISI
Vera Therapeutics pullback a buying opportunity, says Cantor Fitzgerald
A deadly mistake in my prediction…
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
TD Cowen Remains a Buy on Vera Therapeutics (VERA)
Vera Therapeutics initiated with an Outperform at Wolfe Research
See More Headlines

VERA Stock Analysis - Frequently Asked Questions

Vera Therapeutics' stock was trading at $42.29 at the beginning of 2025. Since then, VERA shares have decreased by 32.4% and is now trading at $28.58.
View the best growth stocks for 2025 here
.

Vera Therapeutics, Inc. (NASDAQ:VERA) announced its quarterly earnings results on Thursday, November, 7th. The company reported ($0.85) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.21.

Vera Therapeutics (VERA) raised $66 million in an initial public offering on Friday, May 14th 2021. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI served as the underwriters for the IPO.

Top institutional shareholders of Vera Therapeutics include Avoro Capital Advisors LLC (8.86%), Price T Rowe Associates Inc. MD (6.91%), FMR LLC (4.82%) and Vanguard Group Inc. (4.66%). Insiders that own company stock include Commodore Capital Lp, Sofinnova Venture Partners X,, Carlyle Group Inc, Marshall Fordyce, Beth C Seidenberg, Sean Grant, Joseph R Young, Joanne Curley and Celia Lin.
View institutional ownership trends
.

Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vera Therapeutics investors own include CRISPR Therapeutics (CRSP), Pure Storage (PSTG), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

Last Earnings
11/07/2024
Today
2/23/2025
Next Earnings (Estimated)
5/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VERA
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$65.44
High Stock Price Target
$107.00
Low Stock Price Target
$38.00
Potential Upside/Downside
+129.0%
Consensus Rating
Buy
Rating Score (0-4)
3.20
Research Coverage
10 Analysts

Profitability

Net Income
$-95,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.94 per share

Miscellaneous

Free Float
49,582,000
Market Cap
$1.81 billion
Optionable
Optionable
Beta
1.11
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:VERA) was last updated on 2/23/2025 by MarketBeat.com Staff
From Our Partners